Black Diamond Therapeutics, Inc. BDTX

1.88 (0.02) (1.05%) as of 25 Sep
Market cap
$108.6M
P/E
0.0×
Growth Flags show if company had growth for consecutive years

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Gross Profit

+8 more TTM periods

— — — —
R&D Expenses
39.56 33.56 30.06 28.13
SG&A Expenses
18.58 16.57 15.86 16.43
Operating Income
11.86 12.52 (53.27) (51.90)
Non-operating Income/Expense
9.64 9.85 10.06 9.35
EBT
21.50 22.37 (43.21) (42.55)
Income after Tax
21.50 22.37 (43.21) (42.55)
Net Income Common
21.50 22.37 (43.21) (42.55)
EPS (Basic)
0.38 0.39 (0.77) (0.75)
EBIT Margin
0.00% 0.00% 0.00% 0.00%
EBT margin
0.00% 0.00% 0.00% 0.00%
Net Profit Margin
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Margin
0.00% 0.00% 0.00% 0.00%
EBITDA
12.20 12.85 (53.00) (51.70)
EBIT
11.86 12.52 (53.27) (51.90)
EPS (Diluted, from Cont. Ops)
0.37 0.39 (0.75) (0.74)
EPS (Basic, Consolidated)
0.38 0.39 (0.76) (0.75)
EPS (Basic, from Continuous Ops)
0.38 0.39 (0.76) (0.75)
Income from Continuous Operations
21.50 22.37 (43.21) (42.55)
Consolidated Net Income/Loss
21.50 22.37 (43.21) (42.55)
EBITDA Margin
0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Margin
0.00% 0.00% 0.00% 0.00%

Fold the line items

In millions of $ except per-share values · columns are period end dates